PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Review Article

Volume 8 Issue 1

Enhancing Hypertension Management

Christina Rahm*

July 21, 2026

DOI : 10.56831/PSSRP-08-289

Abstract

Hypertension, or high blood pressure, is a chronic and progressive condition that represents one of the most significant modifiable risk factors for cardiovascular morbidity and mortality worldwide. It is a leading contributor to heart disease, stroke, chronic kidney disease, heart failure, and vascular dementia. In the United States alone, nearly one in three adults is affected, and prevalence continues to rise due to aging populations, sedentary lifestyles, poor dietary patterns, obesity, chronic stress, and metabolic disorders (WHO, 2025). Often referred to as the “silent killer,” hypertension frequently presents without noticeable symptoms, allowing vascular damage to accumulate quietly over years before manifesting as a major cardiovascular event. Despite widespread awareness and the availability of effective pharmacologic therapies, blood pressure control rates remain suboptimal. A substantial percentage of hypertensive individuals either remain undiagnosed, undertreated, or non-adherent to prescribed treatment plans. Barriers to optimal control include inconsistent monitoring, limited patient engagement, therapeutic inertia, socioeconomic disparities, medication side effects, and inadequate lifestyle modification. As a result, uncontrolled hypertension significantly increases hospitalizations, disability-adjusted life years (DALYs), and premature mortality.

The economic burden of hypertension is equally profound. Direct medical costs including hospital admissions, emergency care, medications, and outpatient visits combine with indirect costs such as lost productivity, disability, and long-term care. Collectively, these factors place significant strain on healthcare systems and national economies. Preventive strategies and improved management protocols therefore represent both a clinical and financial imperative.

In recent years, advancements in digital health technologies have transformed the landscape of hypertension management. Home blood pressure monitoring, supported by connected health platforms such as the IDEAL LIFE hypertension management system, has emerged as an evidence-based strategy to improve patient outcomes. Remote monitoring enables real-time data transmission, continuous trend analysis, and early detection of blood pressure variability. This facilitates timely clinical intervention, medication adjustments, and personalized feedback ultimately enhancing adherence and empowering patients to take an active role in their care.

Moreover, integrating technology with structured interval interventions including lifestyle coaching, dietary counseling (e.g., DASH diet adherence), physical activity tracking, stress management, and medication optimization creates a comprehensive and proactive management model. Data-driven insights allow healthcare providers to identify patterns, address modifiable risk factors, and prevent hypertensive crises before complications occur. Studies consistently demonstrate that patients engaged in remote monitoring programs achieve improved blood pressure control, reduced emergency visits, and greater long-term cardiovascular risk reduction compared to standard care alone. This white paper examines the epidemiology of hypertension, its clinical and economic consequences, and current evidence-based management strategies. It further explores how digital health solutions and real-time monitoring technologies can enhance treatment adherence, optimize therapeutic outcomes, and reduce healthcare costs. By bridging traditional clinical care with innovative monitoring systems, hypertension management can evolve from reactive treatment to proactive, precision-based cardiovascular prevention ultimately reinforcing overall vascular health, longevity, and quality of life.

References

  1. Anyaogu CN., et al. “Impact of blood pressure control on stroke and myocardial infarction risk in hypertensive patients with and without diabetes: A narrative review”. Cureus 17.7 (2025): e88984.
  2. Berg S. “4 big ways BP measurement goes wrong, and how to tackle them”. American Medical Association (2025). https://www.ama-assn.org/public-health/prevention-wellness/4-big-ways-bp-measurement-goes-wrong-and-how-tackle-them
  3. Bergmann F., et al. “Systolic blood pressure targets below 120 mm Hg are associated with reduced mortality: A metaanalysis”. Journal of Internal Medicine 297.5 (2025): 479-491.
  4. Casey DE., et al. “2019 AHA/ACC clinical performance and quality measures for adults with high blood pressure: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures”. Circulation: Cardiovascular Quality and Outcomes 12.11 (2019).
  5. Centers for Disease Control and Prevention. “Health and economic benefits of high blood pressure interventions”. U.S. Department of Health and Human Services (2025). https://www.cdc.gov/nccdphp/priorities/high-blood-pressure.html
  6. Goorani S, Zangene S and Imig JD. “Hypertension: A continuing public healthcare issue”. International Journal of Molecular Sciences 26.1 (2025): 123.
  7. Hare AJ, Chokshi N and Adusumalli S. “Novel digital technologies for blood pressure monitoring and hypertension management”. Current Cardiology Reports 15.8 (2021): 11.
  8. IDEAL LIFE Inc. “White paper: Hypertension”. mTelehealth (2025). https://mtelehealth.com/studies/Ideal_Life_White_Paper_on_Hypertension.pdf
  9. Kario K. “Home blood pressure monitoring: Current status and new developments”. American Journal of Hypertension 34.8 (2021): 783-794.
  10. Mills KT, Stefanescu A and He J. “The global epidemiology of hypertension”. Nature Reviews Nephrology 16.4 (2020): 223-237.
  11. Pengpid S and Peltzer K. “Prevalence, awareness, treatment and control of hypertension among adults in Kenya: Cross-sectional national Cross sectional survey”. Eastern Mediterranean Health Journal 26.8 (2020): 923-932.
  12. Razo C., et al. “Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study”. Nature Medicine 28.10 (2022): 2056-2065.
  13. Schutte AE., et al. “Addressing global disparities in blood pressure control: Perspectives of the International Society of Hypertension”. Cardiovascular Research 119.2 (2022): 381-409.
  14. World Health Organization. Hypertension [Fact sheet] (2025). https://www.who.int/news-room/fact-sheets/detail/hypertension
  15. Xu D., et al. “The influence of factors such as anxiety on the white coat effect during the treatment of patients with hypertension”. Journal of Cardiovascular Medicine 23.11 (2022): 359.